Zeleciment basivarsen (z-basivarsen, DYNE-101) is an investigational therapy for myotonic dystrophy type 1 in ongoing Phase 1/2 and Phase 3 development. Dyne initiated the global confirmatory Phase 3 HARMONIA trial in March 2026 with FDA-aligned protocol intended to support conversion from accelerated to traditional approval. The candidate is designed to address disease biology by reducing toxic DMPK RNA.
Regulatory incentives for rare disease treatments, including market exclusivity and development subsidies, are spurring pharmaceutical innovation across the US, Europe, Japan, and Australia, with multiple companies advancing therapies for conditions affecting limited patient populations.
Dyne Therapeutics is preparing a U.S. Accelerated Approval submission for z-rostudirsen in Duchenne muscular dystrophy and gearing up for a Phase 3 trial of z-basivarsen in myotonic dystrophy, while scaling operations to support potential commercialization.
Japan's Ministry of Health, Labour and Welfare granted Orphan Drug designation to Dyne Therapeutics' investigational treatment zeleciment-basivarsen for myotonic muscular dystrophy type 1, adding to existing designations in the U.S. and Europe.
